Abstract:A previously healthy 1-year-old boy presented to the Department of Respiratory Medicine with a 10-day history of cough, wheeze, and fever. Despite therapy with antibiotics (cefaclor, 30 mg/kg/d orally, divided into 3 doses) and bronchodilators (procaterol hydrochloride, 2 μg/kg/d, twice daily) for 7 consecutive days at the local primary health care facility, the child's respiratory status progressively deteriorated and he was referred to our institution. A chest radiograph revealed bilateral patchy consolidation. Streptococcus pneumoniae urinary antigen was positive. Intravenous amoxicillin-clauvulanic acid, inhaled corticosteroids and bronchodilators, and oral mucolytics were administered for a working diagnosis of community-acquired pneumonia. On the second day of hospitalization, the patient developed an irregular macular rash on the face, neck, and trunk. Beta-lactam antibiotic allergy was suspected. Cetirizine hydrochloride was administered and the antibiotic was replaced with meropenem. In the following 3 days the rash transformed into a confluent maculopapular exanthema with blisters and denudation of the epidermis in large patches that involved large areas (roughly 90%) of the body surface (Figure 1, A and B). Multiple erosive lesions developed on the oropharyngeal, anal, and ocular mucosa. In addition, he was febrile and dyspneic. Toxic epidermal necrolysis (TEN) was confirmed and the child was transferred to the pediatric intensive care unit for hypoxemia. In addition to noninvasive ventilation and supportive systemic therapy, he was treated with intravenous methylprednisolone and gamma globulin, plasmapheresis, surgical wound care, and ophthalmic lubricant. Acinetobacter baumannii and Klebsiella pneumoniae were isolated from wound swab cultures and the antibiotic treatment was changed to intravenous tigecycline and polymyxin. During the hospitalization period, fluid balance and creatinine remained stable. The patient's SCORe of Toxic Epidermal Necrosis was 2 (mild) (body surface area involved > 10%, score 1; tachycardia > 120 bpm, score 1).1Bastuji-Garin S. Fouchard N. Bertocchi M. Roujeau J.C. Revuz J. Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.J Invest Dermatol. 2000; 115: 149-153Abstract Full Text Full Text PDF PubMed Scopus (802) Google Scholar The skin reepithelialized progressively (Figure 1, C and D) and the patient was discharged after a 14-week stay. TEN is a potentially life-threatening disorder characterized by widespread epidermal necrosis of skin and mucosa involving greater than 30% of the body surface area.2Alerhand S. Cassella C. Koyfman A. Stevens-Johnson syndrome and toxic epidermal necrolysis in the pediatric population: a review.Pediatr Emerg Care. 2016; 32: 472-476Crossref PubMed Scopus (26) Google Scholar Although the precise pathogenic mechanism is not understood, cutaneous reactions in TEN lead to keratinocyte apoptosis, which may be induced by drugs or infections or be idiopathic. Medications are the most common reported cause. The culprit antibiotic causing TEN in this patient is not certain, because both cephalosporins and beta-lactamase inhibitors may be etiological factors. TEN usually develops between 4 and 28 days after drug intake; however, in rare cases of rechallenge with a drug with similar structure, the disease appears more rapidly, within hours. This might suggest that the TEN developed in response to coamoxiclav, although the immune-related cytotoxic reaction could have been initiated during the initial antibiotic treatment with cefaclor. The management of TEN is challenging, involving a wide array of costly resources, prolonged hospital stays, and potential mortality.2Alerhand S. Cassella C. Koyfman A. Stevens-Johnson syndrome and toxic epidermal necrolysis in the pediatric population: a review.Pediatr Emerg Care. 2016; 32: 472-476Crossref PubMed Scopus (26) Google Scholar The outcomes depend on prompt discontinuation of the suspected causative drug, antimicrobial treatment, wound care, and supportive therapies.

A review on toxic epidermal necrolysis‐like superficial wound lesions: Issue and challenge on 10 clinical entities

Advancement in the Diagnosis and Management of Toxic Epidermal Necrolysis

Toxic Epidermal Necrolysis with Systemic Lupus Erythematosus: Case Report and Review of the Literature

Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review

Recent progress of Stevens-Johnson syndrome/toxic epidermal necrolysis: Diagnosis criteria, pathogenesis and therapy

Toxic Epidermal Necrolysis And Stevens Johnson Syndrome: Report Of Two Cases.

Multidisciplinary Treatment in Toxic Epidermal Necrolysis

The Reflection on the Management of Toxic Epidermal Necrolysis in the Community Setting: an Internist's Perspective

High risk and low prevalence diseases: Stevens Johnson syndrome and toxic epidermal necrolysis

Toxic epidermal necrolysis in hepatitis A infection with acute-on-chronic liver failure: Case report and literature review

Stevens-Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management

Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results

Toxic Epidermal Necrolysis in a Child

Update on Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management

Toxic Epidermal Necrolysis Superimposed on Severe Drug Rash With Eosinophilia and Systemic Symptoms Complicated by Fatal Hemophagocytic Lymphohistiocytosis: A Case Report

Drug-induced Toxic Epidermal Necrolysis with Secondary Aspergillus Fumigatus Infection: a Case Report

Clinical analysis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis

Autologous Skin Cell Suspension Application for Toxic Epidermal Necrolysis: A Case Report

Toxic epidermal necrolysis: management strategies in burns units

Update of etiology and risk factors of toxic epidermal necrolysis

Toxic epidermal necrolysis complicated with respiratory failure in children: A case report